Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019:1165:671-691.
doi: 10.1007/978-981-13-8871-2_33.

Antifibrotic Roles of RAAS Blockers: Update

Ying-Ying Zhang  1 , Ying Yu  1 , Chen Yu  2
Affiliations
Review

Antifibrotic Roles of RAAS Blockers: Update

Ying-Ying Zhang et al. Adv Exp Med Biol. 2019.

Abstract

The rennin-angiotensin-aldosterone system (RAAS) has been well documented in regulating blood pressure, fluid volume, and sodium balance. Overactivity of RAAS promotes both systemic and regional glomerular capillary hypertension, which could induce hemodynamic injury to the glomerulus, leading to kidney damage and renal fibrosis via profibrotic and proinflammatory pathway. Therefore, the use of RAAS inhibitors (i.e., ACEIs, ARBs, and MRAs) as the optional therapy has been demonstrated to prevent proteinuria, and kidney fibrosis and slow the decline of renal function effectively in the process of kidney disease during the last few decades. Recently, several new components of the RAAS have been discovered, including ACE2 and the corresponding ACE2/Ang (1-7)/Mas axis, which are also present in the kidney. Besides the classic RAAS inhibitors target the angiotensin-AT1-aldosterone axis, with the expanding knowledge about RAAS, a number of potential therapeutic targets in this system is emerging. Newer agents that are more specific are being developed. The present chapter outlines the insights of the RAAS agents (classic RAAS antagonists/the new RAAS drugs), and discusses its clinical application in the combat of renal fibrosis.

Keywords: Antagonists; Fibrosis; Renin–angiotensin–aldosterone system (RAAS).

PubMed Disclaimer

Figures

Fig. 33.1
Fig. 33.1
Antifibrotic role of RAAS blockers in renal fibrosis
See this image and copyright information in PMC

References

    1. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42:600–604. doi: 10.1161/01.HYP.0000090323.58122.5C. - DOI - PubMed
    1. Albiston AL, Morton CJ, Ng HL, Pham V, Yeatman HR, Ye S, et al. Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J. 2008;22:4209–4217. doi: 10.1096/fj.08-112227. - DOI - PubMed
    1. Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63–72. doi: 10.1097/HJH.0b013e32800ff5d6. - DOI - PubMed
    1. Andersen K, Hartman D, Peppard T, Hermann D, Van Ess P, Lefkowitz M, et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens. 2012;14:580–587. doi: 10.1111/j.1751-7176.2012.00667.x. - DOI - PMC - PubMed
    1. Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358:548–557. doi: 10.1124/jpet.116.234765. - DOI - PubMed